Medicine
Rethymic 22000 mm implant
Rethymic 22000 mm implant is a prescription medicine containing Allogeneic thymocyte-depleted thymus tissue for intramuscular use, marketed by Sumitomo Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not refrigerate, freeze, agitate, or sterilize RETHYMIC. Store RETHYMIC at…
Key facts
- Active ingredient (INN)
- Allogeneic thymocyte-depleted thymus tissue
- Brand
- Rethymic
- Strength
- 22000 mm
- Dosage form
- Implant
- Route
- Intramuscular
- Packs
- 11 containers
- Marketing authorisation holder
- Sumitomo Pharma
- Manufacturer
- Sumitomo Pharma
- Origin register
- US FDA, United States
- Storage
- Do not refrigerate, freeze, agitate, or sterilize RETHYMIC. Store RETHYMIC at room temperature in the polycarbonate container in the insulated shipping box until ready for use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 October 2021
- Identifiers
- RxCUI 2626464, 2626469DailyMed set ID e0022c28-8cda-4f1e-bcf1-1f440d37ec4aNDC 72359-001Application BLA125685
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 11 container in 1 box / 4 implant in 1 container | 72359-001-01 | Sumitomo Pharma | 8 October 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Allogeneic thymocyte-depleted thymus tissue is a prescription medicine indicated for immune reconstitution in pediatric patients with congenital athymia. It is available as implants for intramuscular use. MedsAcross supplies Allogeneic thymocyte-depleted thymus tissue for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Allogeneic thymocyte-depleted thymus tissueFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- RETHYMIC prescribing information (Sumitomo Pharma) · U.S. National Library of Medicine, DailyMed
Need Rethymic 22000 mm implant for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.